Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection

Cellular and Molecular Immunology

Volumn 13, Issue 1, 2016, Pages 11-35

  Wong, Mun Teng ^a   Chen, Steve S L ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

anti HCV activity; HCV; IFN; innate immunity; ISG

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ADENOSINE DEAMINASE; CORE PROTEIN; DDX60 PROTEIN; GLYCOPROTEIN E2; GUANOSINE TRIPHOSPHATASE; HELICASE; HEPACIVIRIN; HIGH MOBILITY GROUP B1 PROTEIN; IFN INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT 1; IFN INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT 2; IFN INDUCIBLE TRANSMEMBRANE PROTEIN 1; IFN INDUCIBLE TRANSMEMBRANE PROTEIN 2; IFN INDUCIBLE TRANSMEMBRANE PROTEIN 3; IFN STIMULATED GENE 20 KDA PROTEIN; IMMUNITY RELATED GTPASE FAMILY M; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 7; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA; RETINOIC ACID INDUCIBLE GENE 1 LIKE RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOIC ACID RECEPTOR; RIBAVIRIN; RIBONUCLEASE L; RNA SPECIFIC ADENOSINE DEAMINASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; AUTOPHAGY; ENDOPLASMIC RETICULUM STRESS; GENE; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; ISG GENE; REVIEW; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS C; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; PATHOGENICITY; SIGNAL TRANSDUCTION; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84954215381     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.127     Document Type: Review

References (287)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74-81.
2. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436: 930-932.
3. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
4. Lauletta G, Russi S, Conteduca V, Sansonno L. Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol 2012; 2012: 502156.
5. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
6. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006; 80: 11082-11093.
7. Sir D, Liang C, Chen WL, Jung JU, Ou JH. Perturbation of autophagic pathway by hepatitis C virus. Autophagy 2008; 4: 830-831.
8. Dreux M, Chisari FV. Viruses and the autophagy machinery. Cell Cycle 2010; 9: 1295-1307.
9. Dreux M, Chisari FV. Impact of the autophagy machinery on hepatitis C virus infection. Viruses 2011; 3: 1342-1357.
10. Ke PY, Chen SS. Autophagy: a novel guardian of HCV against innate immune response. Autophagy 2011; 7: 533-535.
11. Ke PY, Chen SS. Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 2012; 4: 2251-2290.
12. Ke PY, Chen SS. Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol 2014; 20: 5773-5793.
13. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19: 879-888.
14. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014; 40: 13-24.
15. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci 2008; 1143: 1-20.
16. Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol 2008; 8: 644-654.
17. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578.
18. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137.
19. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014; 426: 1198-1209.
20. Saito T, GaleMJr. Regulation of innate immunity against hepatitis C virus infection. Hepatol Res 2008; 38: 115-122.
21. Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010; 285: 22741-22747.
22. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527.
23. GaleMJr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945.
24. Liu HM, Gale M. Hepatitis C virus evasion from RIG-I-dependent hepatic innate immunity. Gastroenterol Res Pract 2010; 2010: 548390.
25. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.
26. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013; 35: 53-72.
27. Chen SS, Ke PY. Suppression of innate antiviral immunity after hepatitis C virus infection: role of the unfolded protein response and autophagy. In:Hayat MA (ed.) Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Volume 2: Role in General Diseases. Amsterdam: Academic Press, 2014: 137-159.
28. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
29. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012; 13: 214-222.
30. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327.
31. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
32. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014; 2014 Jul 28. doi: 10.1002/hep.27259. [Epub ahead of print].
33. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl 1): S10-S15.
34. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444.
35. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-639.
36. Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34: 286-296.
37. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res 2003; 60: 125-127.
38. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235.
39. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751.
40. Han JH, Shyamala V, Richman KH, Brauer MJ, Irvine B, Urdea MS et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 59 untranslated region and poly(A) tails at the 39 end. Proc Natl Acad Sci USA 1991; 88: 1711-1715.
41. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007; 81: 8374-8383.
42. Jirasko V, Montserret R, Appel N, Janvier A, Eustachi L, Brohm C et al. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J Biol Chem 2008; 283: 28546-28562.
43. Phan T, Beran RK, Peters C, Lorenz IC, Lindenbach BD. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol 2009; 83: 8379-8395.
44. Yi M, Ma Y, Yates J, Lemon SM. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog 2009; 5: e1000403.
45. Dentzer TG, Lorenz IC, Evans MJ, Rice CM. Determinants of the hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. J Virol 2009; 83: 12702-12713.
46. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol 2008; 82: 7624-7639.
47. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4: e1000035.
48. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82: 7964-7976.
49. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-12771.
50. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 2013; 11: 688-700.
51. El-Hage N, Luo G. Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol 2003; 84: 2761-2769.
52. Gao L, Aizaki H, He JW, Lai MM. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 2004; 78: 3480-3488.
53. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. Nat Rev Mol Cell Biol 2006; 7: 373-378.
54. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-1097.
55. Boulant S, Montserret R, Hope RG, Ratinier M, Targett-Adams P, Lavergne JP et al. Structural determinants that target the hepatitis C virus core protein to lipid droplets. J Biol Chem 2006; 281: 22236-22247.
56. Lai CK, Jeng KS, Machida K, Lai MM. Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J Virol 2008; 82: 8838-8848.
57. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007; 3: e103.
58. Atoom AM, Taylor NG, Russell RS. The elusive function of the hepatitis C virus p7 protein. Virology 2014; 462-463: 377-387.
59. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003; 535: 34-38.
60. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330-338.
61. Gentzsch J, Brohm C, Steinmann E, Friesland M, Menzel N, Vieyres G et al. hepatitis c Virus p7 is critical for capsid assembly and envelopment. PLoS Pathog 2013; 9: e1003355.
62. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-281.
63. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89: 1-47.
64. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 2011; 1: 476-486.
65. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002; 2: 675-687.
66. Wei X, Jia ZS, Lian JQ, Zhang Y, Li J, MaL et al. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. J Interferon Cytokine Res 2009; 29: 171-178.
67. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988.
68. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
69. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
70. Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J 2008; 2: 49-59.
71. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103: 6001-6006.
72. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-105.
73. Myong S, Cui S, Cornish PV, Kirchhofer A, Gack MU, Jung JU et al. Cytosolic viral sensor RIG-I is a 59-triphosphate-dependent translocase on double-stranded RNA. Science 2009; 323: 1070-1074.
74. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, GaleMJr. The mitochondrial targeting chaperone 14-3-3 regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 2012; 11: 528-537.
75. Heim MH. HCV innate immune responses. Viruses 2009; 1: 1073-1088.
76. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172.
77. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3: 900-911.
78. Shimoike T, Koyama C, Murakami K, Suzuki R, Matsuura Y, Miyamura T et al. Down-regulation of the internal ribosome entry site (IRES)-mediated translation of the hepatitis C virus: critical role of binding of the stem-loop IIId domain of IRES and the viral core protein. Virology 2006; 345: 434-445.
79. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA et al. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006; 80: 9226-9235.
80. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-490.
81. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol 2011; 85: 5986-5994.
82. Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G et al. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 2007; 81: 202-214.
83. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002; 54: 527-542.
84. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110.
85. Taylor DR, Shi ST, Lai MM. Hepatitis C virus and interferon resistance. Microbes Infect 2000; 2: 1743-1756.
86. Horner SM, Park HS, Gale M Jr. Control of innate immune signaling and membrane targeting by the hepatitis C virus NS3/4A protease are governed by the NS3 helix a0. J Virol 2012; 86: 3112-3120.
87. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA 2008; 105: 14545-14550.
88. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-17722.
89. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997.
90. Bellecave P, Sarasin-Filipowicz M, Donze O, Kennel A, Gouttenoire J, Meylan E et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010; 51: 1127-1136.
91. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-b. Proc Natl Acad Sci USA 2004; 101: 3533-3538.
92. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455: 674-678.
93. Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal 2012; 5: ra20.
94. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788-792.
95. Aguirre S, Maestre AM, Pagni S, Patel JR, Savage T, Gutman D et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog 2012; 8: e1002934.
96. Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 2013; 59: 52-58.
97. Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 2013; 57: 46-58.
98. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995; 69: 3980-3986.
99. Reed KE, Xu J, Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol 1997; 71: 7187-7197.
100. Huang Y, Staschke K, de Francesco R, Tan SL. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication Virology 2007; 364: 1-9.
101. Neddermann P, Quintavalle M, Di Pietro C, Clementi A, Cerretani M, Altamura S et al. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 2004; 78: 13306-13314.
102. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502.
103. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Taguwa S et al. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007; 81: 8953-8966.
104. Gale MJ, Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227.
105. Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001; 284: 1-12.
106. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218.
107. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferoninduced antiviral response. J Virol 2001; 75: 6095-6106.
108. Koo BC, McPoland P, Wagoner JP, Kane OJ, Lohmann V, Polyak SJ. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol 2006; 80: 7885-7893.
109. Taguchi T, Nagano-FujiiM, Akutsu M, Kadoya H, Ohgimoto S, Ishido S et al. Hepatitis C virus NS5A protein interacts with 29, 59-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol 2004; 85: 959-969.
110. Han JQ, Barton DJ. Activation and evasion of the antiviral 29-59 oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 2002; 8: 512-525.
111. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 2000; 67: 173-178.
112. Kanda T, Steele R, Ray R, Ray RB. Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice. J Virol 2009; 83: 8463-8469.
113. Miyasaka Y, Enomoto N, Kurosaki M, Sakamoto N, Kanazawa N, Kohashi T et al. Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-a-mediated apoptosis in Huh7 cells. J Infect Dis 2003; 188: 1537-1544.
114. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses upregulates protein phosphatase 2A. Hepatology 2007; 46: 558-565.
115. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-439.
116. Guergnon J, Godet AN, Galioot A, Falanga PB, Colle JH, Cayla X et al. PP2A targeting by viral proteins: a widespread biological strategy from DNA/RNA tumor viruses to HIV-1. Biochim Biophys Acta 2011; 1812: 1498-1507.
117. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through upregulation of protein phosphatase 2A. Gastroenterology 2004; 126: 263-277.
118. Duong FH, Christen V, Berke JM, Penna SH, Moradpour D, Heim MH. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol 2005; 79: 15342-15350.
119. Larner AC, Jonak G, Cheng YS, Korant B, Knight E, Darnell JE Jr. Transcriptional induction of two genes in human cells by b interferon. Proc Natl Acad Sci USA 1984; 81: 6733-6737.
120. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69: 912-920.
121. Li XL, Ezelle HJ, Hsi TY, Hassel BA. A central role for RNA in the induction and biological activities of type 1 interferons. Wiley Interdiscip Rev RNA 2011; 2: 58-78.
122. Jouan L, Chatel-Chaix L, Melancon P, Rodrigue-Gervais IG, Raymond VA, Selliah S et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. J Hepatol 2012; 56: 70-77.
123. Kim MJ, Hwang SY, Imaizumi T, Yoo JY. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferoninduced ISG15 conjugation. J Virol 2008; 82: 1474-1483.
124. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692.
125. Wang Y, Ye L, Wang X, Li J, Song L, Ho W. Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes. Innate Immun 2013; 19: 193-202.
126. Phipps-Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez-Sesma A. Interferon-b pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathog 2008; 4: e1000193.
127. Kolakofsky D, Kowalinski E, Cusack S. A structure-based model of RIG-I activation. RNA 2012; 18: 2118-2127.
128. Maelfait J, Beyaert R. Emerging role of ubiquitination in antiviral RIG-I signaling. Microbiol Mol Biol Rev 2012; 76: 33-45.
129. Miyashita M, Oshiumi H, Matsumoto M, Seya T. DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling. Mol Cell Biol 2011; 31: 3802-3819.
130. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A et al. Hepatitis C virus induces interferon-and interferon-stimulated genes in primary liver cultures. Hepatology 2011; 54: 1913-1923.
131. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623-655.
132. Pflugheber J, Fredericksen B, Sumpter R Jr, Wang C, Ware F, Sodora DL et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci USA 2002; 99: 4650-4655.
133. Pine R. Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection. J Virol 1992; 66: 4470-4478.
134. Kanazawa N, Kurosaki M, Sakamoto N, Enomoto N, Itsui Y, Yamashiro T et al. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol 2004; 78: 9713-9720.
135. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777.
136. Raychoudhuri A, Shrivastava S, Steele R, Dash S, Kanda T, Ray R et al. Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes. J Virol 2010; 84: 10991-10998.
137. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013; 9: e1003118.
138. Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005; 42: 819-827.
139. Aly HH, Watashi K, Hijikata M, Kaneko H, Takada Y, Egawa H et al. Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. J Hepatol 2007; 46: 26-36.
140. Daffis S, Samuel MA, Suthar MS, Keller BC, GaleMJr, Diamond MS. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol 2008; 82: 8465-8475.
141. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
142. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006; 70: 1032-1060.
143. Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012; 4: 2598-2635.
144. Kang JI, Kwon SN, Park SH, Kim YK, Choi SY, Kim JP et al. PKR protein kinase is activated by hepatitis C virus and inhibits viral replication through translational control. Virus Res 2009; 142: 51-56.
145. Rivas-Estilla AM, Svitkin Y, Lopez Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; 76: 10637-10653.
146. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82: 1665-1678.
147. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003; 77: 3898-3912.
148. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 2005; 79: 6291-6298.
149. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P et al. Hepatitis C virus controls interferon production through PKR activation. PLoS One 2010; 5: e10575.
150. Ventoso I, Sanz MA, Molina S, Berlanga JJ, Carrasco L, Esteban M. Translational resistance of late alphavirus mRNA to eIF2a phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev 2006; 20: 87-100.
151. Robert F, Kapp LD, Khan SN, Acker MG, Kolitz S, Kazemi S et al. Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2.GTP.Met-tRNA(i)(Met) ternary complex availability. Mol Biol Cell 2006; 17: 4632-4644.
152. Shimoike T, McKenna SA, Lindhout DA, Puglisi JD. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res 2009; 83: 228-237.
153. Karamichali E, Foka P, Tsitoura E, Kalliampakou K, Kazazi D, Karayiannis P et al. HCV NS5A co-operates with PKR in modulating HCV IRES-dependent translation. Infect Genet Evol 2014; 26C: 113-122.
154. Terenin IM, Dmitriev SE, Andreev DE, Shatsky IN. Eukaryotic translation initiation machinery can operate in a bacterial-like mode without eIF2. Nat Struct Mol Biol 2008; 15: 836-841.
155. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009; 6: 513-522.
156. Garaigorta U, Heim MH, Boyd B, Wieland S, Chisari FV. Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. J Virol 2012; 86: 11043-11056.
157. Beckham CJ, Parker R. P bodies, stress granules, and viral life cycles. Cell Host Microbe 2008; 3: 206-212.
158. Kedersha N, Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 2002; 30: 963-969.
159. Anderson P, Kedersha N. RNA granules. J Cell Biol 2006; 172: 803-808.
160. Anderson P, Kedersha N. Stress granules. Curr Biol 2009; 19: R397-398.
161. Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol Cell 2009; 36: 932-941.
162. Lloyd RE. Regulation of stress granules and P-bodies during RNA virus infection. Wiley Interdiscip Rev RNA 2013; 4: 317-331.
163. Reineke LC, Lloyd RE. Diversion of stress granules and P-bodies during viral infection. Virology 2013; 436: 255-267.
164. Ruggieri A, Dazert E, Metz P, Hofmann S, Bergeest JP, Mazur J et al. Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Cell Host Microbe 2012; 12: 71-85.
165. Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M et al. Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. J Virol 2011; 85: 6882-6892.
166. Yi Z, Pan T, Wu X, Song W, Wang S, Xu Y et al. Hepatitis C virus coopts Ras-GTPase-activating protein-binding protein 1 for its genome replication. J Virol 2011; 85: 6996-7004.
167. Silverman RH. Viral encounters with 29, 59-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007; 81: 12720-12729.
168. Chakrabarti A, Jha BK, Silverman RH. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011; 31: 49-57.
169. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J Interferon Cytokine Res 2011; 31: 41-47.
170. Kwon YC, Kang JI, Hwang SB, Ahn BY. The ribonuclease Ldependent antiviral roles of human 29, 59-oligoadenylate synthetase family members against hepatitis C virus. FEBS Lett 2013; 587: 156-164.
171. Ishibashi M, Wakita T, Esumi M. 29, 59-Oligoadenylate synthetaselike gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. Biochem Biophys Res Commun 2010; 392: 397-402.
172. Zhou Z, Wang N, Woodson SE, Dong Q, Wang J, Liang Y et al. Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology 2011; 409: 175-188.
173. Degols G, Eldin P, Mechti N. ISG20, an actor of the innate immune response. Biochimie 2007; 89: 831-835.
174. Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011; 411: 180-193.
175. George CX, Gan Z, Liu Y, Samuel CE. Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res 2011; 31: 99-117.
176. Toth AM, Li Z, Cattaneo R, Samuel CE. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem 2009; 284: 29350-29356.
177. George CX, Wagner MV, Samuel CE. Expression of interferoninducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissueselective promoter utilization and alternative splicing. J Biol Chem 2005; 280: 15020-15028.
178. Polson AG, Bass BL, Casey JL. RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase. Nature 1996; 380: 454-456.
179. Luo GX, Chao M, Hsieh SY, Sureau C, Nishikura K, Taylor J. A specific base transition occurs on replicating hepatitis delta virus RNA. J Virol 1990; 64: 1021-1027.
180. Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol 2006; 307: 67-89.
181. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009; 139: 1243-1254.
182. Bailey CC, Huang IC, Kam C, Farzan M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 2012; 8: e1002909.
183. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013; 13: 46-57.
184. Perreira JM, Chin CR, Feeley EM, Brass AL. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 2013; 425: 4937-4955.
185. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011; 7: e1001258.
186. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M, McFarlane N et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013; 57: 461-469.
187. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 2011; 7: e1002337.
188. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013; 13: 452-464.
189. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 2013; 87: 8451-8464.
190. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 2013; 87: 7837-7852.
191. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR et al. IFIT1 is an antiviral protein that recognizes 59-triphosphate RNA. Nat Immunol 2011; 12: 624-630.
192. Liu XY, Chen W, Wei B, Shan YF, Wang C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 2011; 187: 2559-2568.
193. Manes S, del Real G, Martinez AC. Pathogens: raft hijackers. Nat Rev Immunol 2003; 3: 557-568.
194. Schroeder C. Cholesterol-binding viral proteins in virus entry and morphogenesis. Subcell Biochem 2010; 51: 77-108.
195. Raychaudhuri S, Prinz WA. The diverse functions of oxysterolbinding proteins. Annu Rev Cell Dev Biol 2010; 26: 157-177.
196. Holthuis JC, Levine TP. Lipid traffic: floppy drives and a superhighway. Nat Rev Mol Cell Biol 2005; 6: 209-220.
197. Levine T. Short-range intracellular trafficking of small molecules across endoplasmic reticulum junctions. Trends Cell Biol 2004; 14: 483-490.
198. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477: 340-343.
199. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 2013; 9: e1003124.
200. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889.
201. D'Andrea LD, Regan L. TPR proteins: the versatile helix. Trends Biochem Sci 2003; 28: 655-662.
202. Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interferon Cytokine Res 2011; 31: 71-78.
203. Li Y, Li C, Xue P, Zhong B, Mao AP, Ran Y et al. ISG56 is a negativefeedback regulator of virus-triggered signaling and cellular antiviral response. Proc Natl Acad Sci USA 2009; 106: 7945-7950.
204. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J et al. 29-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010; 468: 452-456.
205. Wacher C, Muller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS et al. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 2007; 81: 860-871.
206. Ciechanover A. Tracing the history of the ubiquitin proteolytic system: the pioneering article. Biochem Biophys Res Commun 2009; 387: 1-10.
207. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81: 203-229.
208. Everett RD, Boutell C, Hale BG. Interplay between viruses and host sumoylation pathways. Nat Rev Microbiol 2013; 11: 400-411.
209. Rajsbaum R, Garcia-Sastre A. Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol 2013; 21: 421-429.
210. Chen L, Li S, Li Y, Duan X, Liu B, McGilvray I. Ubiquitin-like protein modifiers and their potential for antiviral and anti-HCV therapy. Expert Rev Proteomics 2013; 10: 275-287.
211. Jeon YJ, Yoo HM, Chung CH. ISG15 and immune diseases. Biochim Biophys Acta 2010; 1802: 485-496.
212. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA 2005; 102: 10200-10205.
213. Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 2005; 336: 496-506.
214. Morales DJ, Lenschow DJ. The antiviral activities of ISG15. J Mol Biol 2013; 425: 4995-5008.
215. Lu G, Reinert JT, Pitha-Rowe I, Okumura A, Kellum M, Knobeloch KP et al. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell Mol Biol (Noisy-le-grand) 2006; 52: 29-41.
216. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol Cell Biol 2010; 30: 2424-2436.
217. Okumura F, Okumura AJ, Uematsu K, Hatakeyama S, Zhang DE, Kamura T. Activation of double-stranded RNA-activated protein kinase (PKR) by interferon-stimulated gene 15 (ISG15) modification down-regulates protein translation. J Biol Chem 2013; 288: 2839-2847.
218. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 2005; 79: 13974-13983.
219. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 2007; 104: 1371-1376.
220. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol 2010; 91: 382-388.
221. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog 2011; 7: e1002289.
222. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277: 9976-9981.
223. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25: 2358-2367.
224. Kim JH, Luo JK, Zhang DE. The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008; 181: 6467-6472.
225. Malakhova OA, Zhang DE. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem 2008; 283: 8783-8787.
226. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584-1591.
227. Murray EJ, Burden F, Horscroft N, Smith-Burchnell C, Westby M. Knockdown of USP18 increases a 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells. Antimicrob Agents Chemother 2011; 55: 4311-4319.
228. Asahina Y, Izumi N, Hirayama I, Tanaka T, Sato M, Yasui Y et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 1396-1405.
229. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039.
230. Chen L, Li S, McGilvray I. The ISG15/USP18 ubiquitin-like pathway (ISGylation system) in hepatitis C virus infection and resistance to interferon therapy. Int J Biochem Cell Biol 2011; 43: 1427-1431.
231. Seo JY, Yaneva R, Cresswell P. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 2011; 10: 534-539.
232. Helbig KJ, Beard MR. The role of viperin in the innate antiviral response. J Mol Biol 2014; 426: 1210-1219.
233. Fitzgerald KA. The interferon inducible gene: viperin. J Interferon Cytokine Res 2011; 31: 131-135.
234. Mattijssen S, Pruijn GJ. Viperin, a key player in the antiviral response. Microbes Infect 2012; 14: 419-426.
235. Wang X, Hinson ER, Cresswell P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2007; 2: 96-105.
236. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 2012; 120: 778-788.
237. Chan YL, Chang TH, Liao CL, Lin YL. The cellular antiviral protein viperin is attenuated by proteasome-mediated protein degradation in Japanese encephalitis virus-infected cells. J Virol 2008; 82: 10455-10464.
238. Seo JY, Yaneva R, Hinson ER, Cresswell P. Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity. Science 2011; 332: 1093-1097.
239. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005; 42: 702-710.
240. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 2011; 54: 1506-1517.
241. Wang S, Wu X, Pan T, Song W, Wang Y, Zhang F et al. Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33. J Gen Virol 2012; 93: 83-92.
242. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013; 38: 92-105.
243. Kielian M, Rey FA. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 2006; 4: 67-76.
244. Vaney MC, Rey FA. Class II enveloped viruses. Cell Microbiol 2011; 13: 1451-1459.
245. Brodsky LI, Wahed AS, Li J, Tavis JE, Tsukahara T, Taylor MW. A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. PLoS One 2007; 2: e584.
246. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 2012; 56: 2082-2093.
247. Fusco DN, Brisac C, John SP, Huang YW, Chin CR, Xie T et al. A genetic screen identifies interferon-A effector genes required to suppress hepatitis C virus replication. Gastroenterology 2013; 144: 1438-1349.
248. Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hofmann O et al. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol 2012; 56: 326-333.
249. Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 2003; 12: 5-14.
250. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA 2009; 106: 16410-16415.
251. Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-A in lipogenesis and viral assembly. Nat Med 2013; 19: 722-729.
252. Dansako H, Yamane D, Welsch C, McGivern DR, Hu F, Kato N et al. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating Toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS Pathog 2013; 9: e1003345.
253. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
254. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
255. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315-1335.
256. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kB. Proc Natl Acad Sci USA 2001; 98: 9599-9604.
257. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-37488.
258. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L et al. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 2007; 46: 58-65.
259. Jung JH, Park JH, Jee MH, Keum SJ, Cho MS, Yoon SK et al. Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol 2011; 85: 9359-9368.
260. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
261. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-452.
262. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-1075.
263. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and selfkilling: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752.
264. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21: 2861-2873.
265. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8: 931-937.
266. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Molecular Cell 2010; 40: 280-293.
267. Orvedahl A, MacPherson S, Sumpter R Jr, Talloczy Z, Zou Z, Levine B. Autophagy protects against Sindbis virus infection of the central nervous system. Cell Host Microbe 2010; 7: 115-127.
268. Shelly S, Lukinova N, Bambina S, Berman A, Cherry S. Autophagy is an essential component of Drosophila immunity against vesicular stomatitis virus. Immunity 2009; 30: 588-598.
269. Munz C. Enhancing immunity through autophagy. Annu Rev Immunol 2009; 27: 423-449.
270. Orvedahl A, Levine B. Eating the enemy within: autophagy in infectious diseases. Cell Death Differ 2009; 16: 57-69.
271. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol 2009; 10: 461-470.
272. Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009; 5: 527-549.
273. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-335.
274. Sir D, Chen WL, Choi J, Wakita T, Yen TS, Ou JH. Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. Hepatology 2008; 48: 1054-1061.
275. Dreux M, Gastaminza P, Wieland SF, Chisari FV. The autophagy machinery is required to initiate hepatitis C virus replication. Proc Natl Acad Sci USA 2009; 106: 14046-14051.
276. Tanida I, Fukasawa M, Ueno T, Kominami E, Wakita T, Hanada K. Knockdown of autophagy-related gene decreases the production of infectious hepatitis C virus particles. Autophagy 2009; 5: 937-945.
277. Ke PY, Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011; 121: 37-56.
278. Huang H, Kang R, Wang J, Luo G, Yang W, Zhao Z. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulumstress to induce autophagy. Autophagy 2013; 9: 175-195.
279. Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray RB. Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol 2012; 86: 8705-8712.
280. Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology 2011; 53: 406-414.
281. Kim SJ, Syed GH, Siddiqui A. Hepatitis C Virus induces the mitochondrial translocation of Parkin and subsequent mitophagy. PloS Pathog 2013; 9: e1003285.
282. Gregoire IP, Rabourdin-Combe C, Faure M. Autophagy and RNA virus interactomes reveal IRGM as a common target. Autophagy 2012; 8: 1136-1137.
283. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18: 131-140.
284. Jackson RJ, Standart N. How do microRNAs regulate gene expression Sci STKE 2007; 2007: 1.
285. Zhou R, O'Hara SP, Chen XM. MicroRNA regulation of innate immune responses in epithelial cells. Cell Mol Immunol 2011; 8: 371-379.
286. Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J 2014; 11: 64.
287. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013; 9: e1003248.